Kaiser Permanente Research radio recently interviewed Dr. Michael A Bookman, an oncologist and investigator with Kaiser, discussing his participation in an international clinical trial sponsored by AbbVie, focusing on a PARP inhibitor called Veliparib to treat ovarian cancer—a disease often called the “silent killer.”
Sponsored by AbbVie with collaborators including Gynecologic Oncology Group and Australia New Zealand Gynecological Oncology Group, this Phase III, randomized, placebo-controlled study involves 1040 patients taking Veliparib. The study started in 2015 and is scheduled to conclude in the summer of 2020. With clinical investigator sites all over the world, Kaiser Permanente represents a health system and research power house of a participant in the San Francisco Bay Area.
Results to Date
This international trial sponsored by AbbVie has found thus far that the addition of veliparib halted the progression of serious ovarian cancer for 6 months to a year. Investigators, led by Kaiser Permanente oncologist Michael A. Brookman, MD and Ramey Little, MD published these important findings in a New England Journal of Medicine titled (“Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.” The results were recently presented at the European Society of Medical Oncology in Barcelona, Spain.
What is Veliparib?
A PARP inhibitor, Veliparib is a potential anti-cancer drug that can kill cancer cells by blocking the protein called PAPR, thereby preventing the repair of DNA or genetic damage in the cancer cells and possibly making them more susceptible to anticancer treatments. Veliparib may make the whole brain radiation treatment work more effectively against brain metastases from NSCLC. It has been shown to potentiate the effects of many chemotherapeutics and hence is part of many combination clinical trials.
As of this writing at least 102 clinical trials involving veliparib were registered with the FDA.
Kaiser Permanente, a power-house health system based in California operates a massive research operation. At any given time, Kaiser is conducting 350 adult cancer trials; 120 pediatric cancer trials and over 10,000 Kaiser patients have participate in cancer clinical trials over the past decades.
Michael A. Brookman, MD; Dr. Bookman joined Kaiser Permanente Northern California in 2017 as medical director of gynecologic oncology therapeutics. Trained at Harvard Medical School, Dr. Bookman has more than 3 decades of experience treating women with gynecologic cancers in national and international clinical research organizations including Fox Chase Center in Philadelphia and University of Arizona.
Call to Action: Listen to Dr. Bookman’s interview in Kaiser Permanente Division of Research, Spotlight. Do you have an ovarian cancer diagnosis? Dr. Brookman is a renowned expert in this field of cancer.